null

SMILES: COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C

InChI Key: InChIKey=CWEBLBDEUUBLRL-UHFFFAOYSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 337707   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Mitogen-activated protein kinase 14 (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4	n/a	n/a	n/a	n/a	n/a	n/a
RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED US Patent					Assay Description The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...				US Patent US9751837 (2017) BindingDB Entry DOI: 10.7270/Q2028TP7
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	68	n/a	n/a	n/a	n/a	n/a	n/a
RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED US Patent					Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...				US Patent US9751837 (2017) BindingDB Entry DOI: 10.7270/Q2028TP7
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	124	n/a	n/a	n/a	n/a	n/a	n/a
RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED US Patent					Assay Description Method 1The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the...				US Patent US9751837 (2017) BindingDB Entry DOI: 10.7270/Q2028TP7
					More data for this Ligand-Target Pair
Baculoviral IAP repeat-containing protein 2 [174-256] (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...				US Patent US10392346 (2019) BindingDB Entry DOI: 10.7270/Q2N018WV
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	124	n/a	n/a	n/a	n/a	n/a	n/a
Oxular Acquisitions Limited US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US10941115 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	124	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US10392346 (2019) BindingDB Entry DOI: 10.7270/Q2N018WV
					More data for this Ligand-Target Pair
Mitogen-activated protein kinase 14 (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	4	n/a	n/a	n/a	n/a	n/a	n/a
Oxular Acquisitions Limited US Patent					Assay Description p38 MAPKα Method 2: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...				US Patent US10941115 (2021)
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	68	n/a	n/a	n/a	n/a	n/a	n/a
Oxular Acquisitions Limited US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US10941115 (2021)
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM337707 (US10392346, Example 17(am) | US10941115, Example 1...) Show SMILES COc1c(NC(=O)Nc2ccc(Oc3ccnc(Nc4ccc(C(O)=O)c(c4)N(C)C)c3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C Show InChI InChI=1S/C37H40N6O7S/c1-37(2,3)22-18-29(34(49-6)30(19-22)42-51(7,47)48)41-36(46)40-28-14-15-32(26-11-9-8-10-25(26)28)50-24-16-17-38-33(21-24)39-23-12-13-27(35(44)45)31(20-23)43(4)5/h8-21,42H,1-7H3,(H,38,39)(H,44,45)(H2,40,41,46)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	68	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US10392346 (2019) BindingDB Entry DOI: 10.7270/Q2N018WV
					More data for this Ligand-Target Pair